Open Access

Table 2

Characteristics of the included studies.

Author year (ref.) Country Number (sex) Age Type of disease Duration of treatment Control (number at entry) Treatment group (number at entry) Time of measures Type of study
Abbase et al. 201724 Iraq 40 (M/F) 42.62 ± 13.84 Peptic ulcer disease 14 days Standard triple therapy (N = 19) Curcumin (1500 mg/day) + standard triple therapy (N = 21) Baseline and after 6 weeks RCT
Alizadeh et al. 201725 Iran 60 (M) 30.27 ± 3.99 Infertile oligoasthenospermia 10 weeks Placebo (n = 30) Curcumin nanomicelle 80 mg/day (n = 30) Baseline and end of study RCT
DiSilvestro et al. 201226 USA 38 (M/F) 47.5 ± 10.5 Healthy 4 weeks Placebo (n = 19) Curcuma Longa root powder 400 mg/day (n = 19) Before and after treatment RCT
Hejazi et al. 201627 Iran 40 (M) 70.71 ± 8.20 Prostate cancer treated with radiotherapy 3 months Placebo (n = 23) Curcuminoids 3 g/day (n = 22) Baseline and after 3 months RCT
Jimenez- Osorio et al. 201628 Mexico 101 (M/F) 40.55 ± 3.05 Non-diabetic or diabetic proteinuric chronic kidney disease 8 weeks Placebo groups: Turmeric (320 mg curcumin /day: Before and after treatment RCT
Non-diabetic proteinuric CKD (n = 26) Non-diabetic proteinuric CKD (n = 24)
55.6 ± 1.55 Diabetic proteinuric CKD (n = 23) Diabetic proteinuric CKD (n = 28)
Judaki et al. 201718 Iran 100 (M/F) 54.15 ± 16.09 Chronic gastritis 4 weeks Standard triple therapy (N = 50) Standard triple therapy +Turmeric tablet (700 mg three times/day) (N = 50) Before and after treatment RCT
Nasseri et al. 201729 Iran 68 (M/F) 26.79 ± 6.57 P-Thalassemia 12 weeks Placebo (n = 34) Curcumin 1000 mg/day (n = 34) Baseline and after 12 weeks RCT
Pakfetrat et al. 201519 Iran 50 (M) 53.6 ± 14.7 Hemodialysis 8 weeks Placebo (n = 25) Turmeric 1500 mg/day (n = 25) Before and after treatment RCT
patients
Panahi et al. 201230 Iran 96 (M) 47.9 ± 9.6 Veterans of the Iraq-Iran war with chronic pruritus 4 weeks Placebo (n = 50) Curcuminoids 1 g/day (n = 46) + 5 mg bioperine Before and after treatment RCT
Panahi et al. 2014 a31 Iran 89 (M) 50.97 ± 7.27 Sulfur mustard Iraq-Iran war chronic pulmonary complications 4 weeks placebo (n = 44) Curcuminoids 1500 mg/day + piperine 15 mg/day (n = 45) Before and after treatment RCT
Panahi et al. 2014 b32 Iran 80 (M/F) 58.95 ± 15.31 Solid cancer 8 weeks Placebo (n = 40) Curcuminoids 900 mg/day (n = 40) Before and after treatment RCT
Panahi et al. 2015 a33 Iran 117 (M/F) 44.13 ± 9.18 Metabolic syndrome 8 weeks Placebo (n = 58) Curcuminoids 1 g/day + 10 mg piperine (n = 59) Before and after treatment RCT
Panahi et al. 2015 b34 Iran 40 (M/F) 57.44 ± 8.91 Knee Osteoarthritis 6 weeks Placebo (n= 21) Curcuminoid 1500 mg/day + 15 mg piperine (n= 19) Before and after treatment RCT
Panahi et al. 201620 Iran 118 (M/F) 42 ± 7.5 Type 2 diabetes 8 weeks Placebo Curcuminoids 1000 mg/day + piperine 10 mg Before and after treatment RCT
Roohi et al. 201735 Iran 22 (M) 24.85 ± 2.2 Active healthy males 1 week Placebo (n = 11) Curcuminoids 90 mg (n = 11) Before and after treatment RCT
Srivastava et al. 201636 India 160 (M/F) 50.25 ± 8.35 Osteoarthritis of knee 4 months Placebo (n = 82) Curcuma longa extract 1000 mg/day (n = 78) At day 0, 60, and 120 RCT
Sudheeran et al. 201621 India 60 (M/F) 33 ± 7 Occupational stress- related anxiety and fatigue 30 days Placebo (n = 20) Formulated curcuminoids 1000 mg/day (n = 20) Before and after treatment RCT
Standard curcuminoids (782 mg curcumin) (n = 20)

Male (M); female (F); randomized controlled trial (RCT); Age was expressed as mean ± SD or range.

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.